Please assess the completion status of the following clinical trial:

Trial Title: A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed high grade small cell neuroendocrine carcinoma.~* Patients can either have:~  * Limited stage disease with CR or PR OR~ * Extensive stage disease with CR or good PR~* Patients must have discontinued other chemotherapies at least 3 weeks prior to randomisation.~* Prior radiation therapy to the chest is allowed but must be completed at least 3 weeks prior to randomisation.~* ECOG Performance Status 0 to 2.~* Adequate bone marrow, liver, and renal function as assessed by the following:~  * Hemoglobin ≥ 9.0 g/dl~ * Absolute neutrophil count (ANC) ≥ 1,500/mm3~ * Platelet count ≥ 100,000/mm3~ * Total bilirubin ≤ 2.0 times the upper limit of normal~ * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (≤ 5x ULN for patients with liver involvement)~ * International Normalized Ratio for Prothrombin Time (PT-INR) ≤ 1.5 and activated partial prothrombin time (aPTT) within 5% of normal limits for patient NOT on anticoagulation.~ * Estimated Glomerular Filtration Rate (eGRF) \> 50 ml/min .~* Male or female aged \>18 years~* Patients must be able and willing to sign a written informed consent. A signed informed consent must be appropriately obtained prior to any study specific procedures.~* Patients must be able to swallow and retain oral medication.~* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomisation and must agree to use adequate contraception prior to randomisation and for the duration of study participation.~Exclusion Criteria:~* Life expectancy less than 3 months.~* Substance abuse, medical, psychological, or social condition that may interfere with the patient's participation in the study or evaluation of the study results.~* Severe cardiac or renal disease.~* Frank hypothyroidism.~* Hyponatraemia.~* Known or suspected allergy to lithium.~* Women who are pregnant or breast-feeding.~* Inability to comply with protocol and /or not willing or not available for follow-up assessments.~* Significant psychiatric or neurologic illness (prior known psych/cognitive/CNS pathology eg CVA; known or prior brain metastases~* Current lithium therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI with lithium (Type: EXPERIMENTAL): Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
- Standard (Type: NO_INTERVENTION): Prophylactic cranial irradiation alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).